Aardvark Therapeutics, Inc. Common Stock AARD Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $16.57M+114% | $14.3M+77.4% | $13.74M+238% | $13.15M+226% | $7.76M+543% | ||
| $5.9M+117% | $4.41M+217% | $3.97M+287% | $2.7M+33.2% | $2.72M+215% | ||
| $22.46M+115% | $18.7M+97.9% | $17.7M+248% | $15.85M+161% | $10.47M+382% | ||
| -$22.46M-115% | -$18.7M-97.9% | -$17.7M-248% | -$15.85M-161% | -$10.47M-382% | ||
| $876K-24.5% | $1.11M+64.8% | $1.39M+52.6% | $1.48M+137% | $1.16M+16,671% | ||
| -$21.59M-132% | -$17.6M-100% | -$16.32M-290% | -$14.37M-164% | -$9.31M-327% | ||
| -$0.99-39.4% | -$0.81+62.8% | -$0.75+28.6% | -$0.66+51.8% | -$0.71-29.1% | ||
| -$22.45M-115% | -$18.69M-98.0% | -$17.69M-248% | -$15.84M-161% | -$10.47M-382% | ||
| -$22.46M-115% | -$18.7M-97.9% | -$17.7M-248% | -$15.85M-161% | -$10.47M-382% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Aardvark Therapeutics, Inc. Common Stock profitable?
- Aardvark Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $69.9M over the trailing twelve months.
- What is Aardvark Therapeutics, Inc. Common Stock's earnings per share?
- Aardvark Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-3.21.
- Where does Aardvark Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.